L
LCTX
Lineage Cell The
1.280
-0.010-0.78%After Hours: 1.290 +0.010 +0.78%18:39 07/10 EDT
OPEN/PREV CLOSE1.290/1.290
TODAY RANGE1.250-1.300
VOL738.91K
MARKET CAP319.10M
52 WEEK RANGE0.9296-2.090
AVG VOL (3M)1.53M
% TURNOVER0.30%
TURNOVER--
P/E (TTM)-4.5796
% RANGE3.49%
EPS(TTM)-0.2795
P/E(FORWARD)-21.3333
P/B5.92
BVPS0.2161
DIVIDEND--
P/S21.37
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP303.37M
SHARES OUTSTANDING249.30M
NEXT EARNINGS08/10-08/14
FREE FLOAT237.01M
LOT SIZE1
EX-DATE11/29/2018
News
Press Releases
Financial Reports
Profile
Benzinga·07/01 08:05
Transcript: Lineage Cell Therapeutics Q1 2026 Earnings Conference Call
TipRanks·06/12 22:53
Lineage Cell Shareholders Reaffirm Governance and Executive Pay
TipRanks·05/26 17:49
H.C. Wainwright Reaffirms Their Buy Rating on Lineage Therap (LCTX)
TipRanks·05/14 00:12
Lineage Cell Therapeutics Highlights R&D Momentum Amid Losses
TipRanks·05/13 11:21
Canaccord Genuity Reaffirms Their Buy Rating on Lineage Therap (LCTX)
Seeking Alpha·05/13 01:52
Lineage targets operations into Q2 2028 as it launches COR1 and scales ILT1 manufacturing
TipRanks·05/12 22:11
Lineage Cell Therapeutics reports Q1 EPS (3c), consensus (2c)
TipRanks·05/12 22:10
Lineage Cell sees cash, equivalents funding operations into 2Q28
Seeking Alpha·05/12 20:03
Lineage Cell Therapeutics GAAP EPS of -$0.03 misses by $0.01, revenue of $1.72M misses by $1.36M
Dow Jones·05/12 20:02
*Lineage Cell Therapeutics 1Q Loss/Shr 3c >LCTX
Dow Jones·05/12 20:02
*Lineage Cell Therapeutics 1Q Rev $1.73M >LCTX
Dow Jones·05/12 20:01
Press Release: Lineage Cell Therapeutics Reports -2-